AU2001275651A1 - Curcumin derivatives with improved water solubility compared to curcumin and medicaments containing the same - Google Patents

Curcumin derivatives with improved water solubility compared to curcumin and medicaments containing the same

Info

Publication number
AU2001275651A1
AU2001275651A1 AU2001275651A AU7565101A AU2001275651A1 AU 2001275651 A1 AU2001275651 A1 AU 2001275651A1 AU 2001275651 A AU2001275651 A AU 2001275651A AU 7565101 A AU7565101 A AU 7565101A AU 2001275651 A1 AU2001275651 A1 AU 2001275651A1
Authority
AU
Australia
Prior art keywords
curcumin
derivatives
water solubility
improved water
medicaments containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001275651A
Inventor
Barbara Bertram
Manfred Hergenhahn
Bernd L. Sorg
Manfred Wiessler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of AU2001275651A1 publication Critical patent/AU2001275651A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/203Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to curcumin derivatives with improved water solubility compared to curcumin, which are characterized in that the curcumin part is linked to a monosaccharide, oligosaccharide or polysaccharide, and to medicaments containing these derivatives. The curcumin derivatives according to the invention are particularly suitable to prevent and treat cancer, chronic-inflammatory diseases and diseases associated with a retrovirus infection.
AU2001275651A 2000-06-30 2001-06-28 Curcumin derivatives with improved water solubility compared to curcumin and medicaments containing the same Abandoned AU2001275651A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10031955A DE10031955A1 (en) 2000-06-30 2000-06-30 Curcumin derivatives with improved water solubility compared to curcumin and medicaments containing them
DE10031955 2000-06-30
PCT/DE2001/002337 WO2002002582A1 (en) 2000-06-30 2001-06-28 Curcumin derivatives with improved water solubility compared to curcumin and medicaments containing the same

Publications (1)

Publication Number Publication Date
AU2001275651A1 true AU2001275651A1 (en) 2002-01-14

Family

ID=7647388

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001275651A Abandoned AU2001275651A1 (en) 2000-06-30 2001-06-28 Curcumin derivatives with improved water solubility compared to curcumin and medicaments containing the same

Country Status (7)

Country Link
US (1) US20030153512A1 (en)
EP (1) EP1299406B1 (en)
AT (1) ATE307819T1 (en)
AU (1) AU2001275651A1 (en)
CA (1) CA2414605A1 (en)
DE (2) DE10031955A1 (en)
WO (1) WO2002002582A1 (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030149113A1 (en) * 2001-10-12 2003-08-07 Caplan Michael J. Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US7205151B2 (en) 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US20040115290A1 (en) 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US7270835B2 (en) 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7718198B2 (en) 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
US7279185B2 (en) 2001-10-26 2007-10-09 Metaproteonics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
ATE482696T1 (en) * 2001-10-26 2010-10-15 Metaproteomics Llc CUCUMINOID COMPOSITIONS WITH SYNERGISTIC INHIBITION OF THE EXPRESSION AND/OR ACTION OF CYCLOOXYGENASE-2
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
EP1527127B1 (en) 2002-07-05 2009-02-11 Exxonmobil Chemical Patents Inc. Functionalized elastomer nanocomposite
DE10245988B4 (en) * 2002-10-01 2005-01-27 Dr. André Rieks, Labor für Enzymtechnologie GmbH New curcumin derivatives for use in cosmetics, pharmaceuticals and nutrition
AU2003270283A1 (en) * 2002-10-01 2004-04-23 Dr. Andre Rieks - Labor Fur Enzymtechnologie Gmbh Novel curcumin/tetrahydrocurcumin derivatives for using in cosmetics, pharmaceuticals and for nutrition
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2004080396A2 (en) * 2003-03-07 2004-09-23 The University Of Texas Md Anderson Cancer Center Liposomal curcumin for treatment of cancer
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
JP2005041817A (en) * 2003-07-23 2005-02-17 Japan Science & Technology Agency Curcuminoid glycoside and method for producing the same
US7205011B2 (en) * 2003-11-14 2007-04-17 Board Of Regents, Acting For And On Behalf Of, University Of Arizona Anti-inflammatory activity of a specific turmeric extract
US8841326B2 (en) 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
US8784881B2 (en) * 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
US20080103213A1 (en) * 2004-03-05 2008-05-01 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of neurofibromatosis
EP1824496A4 (en) * 2004-11-17 2008-07-16 Joanne Mclaurin Compositions comprising scyllo-inositol derivatives and methods to treat disorders of protein aggregation
WO2007119108A2 (en) * 2005-10-13 2007-10-25 Waratah Pharmaceuticals Inc. Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
US20070197452A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Treatment of amyloid-related diseases
NZ571181A (en) * 2006-03-09 2011-12-22 Waratah Pharmaceuticals Inc A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation
US20110028719A1 (en) * 2006-05-19 2011-02-03 Jacek Slon-Usakiewicz Screening methods for amyloid beta modulators
WO2008034244A1 (en) * 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
US20080075671A1 (en) * 2006-09-22 2008-03-27 Di Mauro Thomas M Intranasally administering curcumin to the brain to treat alzheimer's disease
JP2010506836A (en) * 2006-10-12 2010-03-04 リサーチ ファウンデイション オブ ザ シティー ユニヴァーシティ オブ ニューヨーク Novel curcumin and tetrahydrocurcumin derivatives
WO2008051474A1 (en) * 2006-10-19 2008-05-02 The Uab Research Foundation Water soluble curcumin-based compounds
JP2010510254A (en) * 2006-11-24 2010-04-02 ワラタ ファーマシューティカルズ, インコーポレイテッド Combination treatment for Alzheimer's disease and related neurodegenerative diseases
JP5124712B2 (en) * 2006-12-28 2013-01-23 マイスターバイオ株式会社 Method for producing polyphenol glycoside
FR2913733B1 (en) 2007-03-14 2009-06-26 Technofan Sa FAN WITH MEANS OF FOLLOW-UP OF WEAR
ES2425264T3 (en) * 2007-04-12 2013-10-14 Waratah Pharmaceuticals, Inc. Use of cyclohexanehexol derivatives in the treatment of eye diseases
WO2008124931A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis
WO2008124930A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
WO2008124929A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF α-SYNUCLEINOPATHIES
US8383865B2 (en) * 2007-04-17 2013-02-26 Codman & Shurtleff, Inc. Curcumin derivatives
JP2010524959A (en) 2007-04-17 2010-07-22 コドマン・アンド・シャートレフ・インコーポレイテッド Nasal administration of curcumin in a helium gas bolus to treat Alzheimer's disease
WO2009023357A2 (en) * 2007-05-25 2009-02-19 University Of Rochester Curcumin derivatives and their use as radioprotectors
US7745670B2 (en) * 2008-06-27 2010-06-29 Codman & Shurtleff, Inc. Curcumin-Resveratrol hybrid molecule
US7985776B2 (en) 2008-06-27 2011-07-26 Codman & Shurtleff, Inc. Iontophoretic delivery of curcumin and curcumin analogs for the treatment of Alzheimer's Disease
WO2010033580A2 (en) 2008-09-19 2010-03-25 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Curcumin conjugates for treating and preventing cancers
JP2012505162A (en) * 2008-10-09 2012-03-01 ワラタ ファーマシューティカルズ, インコーポレイテッド Use of scyllo-inositol for treating macular degeneration related disorders
US20100286585A1 (en) * 2009-01-26 2010-11-11 Codman & Shurtleff, Inc. Shunt Delivery of Curcumin
US7723515B1 (en) * 2009-01-26 2010-05-25 Codman & Shurtleff, Inc. Methylene blue—curcumin analog for the treatment of alzheimer's disease
KR101157995B1 (en) * 2009-04-28 2012-06-25 차의과학대학교 산학협력단 Novel bis-3-hydroxy-4-methyl-phenyl Derivatives and Methods for Preparing the Same
US9446145B2 (en) 2009-12-02 2016-09-20 Research Foundation Of The City University Of New York Curcumin-antibody conjugates as anti-cancer agents
WO2011082290A2 (en) 2009-12-31 2011-07-07 Organomed Corporation Formulations from natural products, turmeric, and aspirin
WO2011106691A2 (en) 2010-02-26 2011-09-01 Research Foundation Of The City University Of New York Curcumin derivatives
KR20160074015A (en) 2010-06-17 2016-06-27 캘리포니아 인스티튜트 오브 테크놀로지 Methods and systems for modulating hormones and related methods, agent and compositions
WO2012004744A2 (en) 2010-07-05 2012-01-12 Polymer Technologies International (Eou) Polymeric composition for ocular devices
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US10258691B2 (en) 2014-06-03 2019-04-16 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies
US10532045B2 (en) 2013-12-18 2020-01-14 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US10349884B2 (en) 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
GB2507884B (en) 2011-06-03 2019-10-23 Signpath Pharma Inc Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US12004868B2 (en) 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
EP2945570A1 (en) 2013-01-15 2015-11-25 Dave, Jagrat Natavar Toric-diffractive lens
EP2983618B1 (en) 2013-04-10 2019-04-17 Dave, Jagrat Natavar Phakic lens device with openings and concentric annular zones
CN103396462A (en) * 2013-08-10 2013-11-20 湖州师范学院 Curcumin glucoside and preparation method and application thereof in treating Parkinson disease
JP6224966B2 (en) * 2013-09-12 2017-11-01 ハウス食品グループ本社株式会社 Method for producing monoglycoside of curcuminoid
EP3071190A4 (en) * 2013-11-22 2017-05-31 Signpath Pharma Inc. Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders
US20170304047A1 (en) 2014-09-02 2017-10-26 Jagrat Natavar DAVE Intraocular lens customized for astigmatism or combined astigmatism and presbyopia
KR102181659B1 (en) 2016-04-27 2020-11-24 사인패스 파마 인코포레이티드 Prevention of drug-induced atrioventricular blockade
US10076552B2 (en) 2016-08-09 2018-09-18 DATT MEDIPRODUCTS LIMITED and DATT LIFE SCIENCE PVT. LTD. Multifunctional formulation comprised of natural ingredients and method of preparation/manufacturing thereof
EP4065152A1 (en) 2019-11-25 2022-10-05 Institut National de la Santé et de la Recherche Médicale (INSERM) Trem-1 inhibitors for the treatment of vaso-occlusions and tissue injuries in patients suffering from sickle cell disease
US20240173376A1 (en) 2021-03-12 2024-05-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Trem-1 inhibitors for the treatment of marfan syndrome
CN113318116B (en) * 2021-06-17 2023-08-25 成都奥睿药业有限公司 Use of curcumin difluoro boron and its derivative
WO2023061946A1 (en) 2021-10-11 2023-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of trem-1 for predicting and preventing postoperative complications after cardiac surgery with cardiopulmonary by-pass

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4999205A (en) * 1989-08-17 1991-03-12 Kalamazoo Holdings, Inc. Curcumin complexed on water-dispersible substrates
IL112205A0 (en) * 1994-01-06 1995-03-15 Res Dev Foundation Curcumin, analogues of curcumin and novel uses thereof
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis

Also Published As

Publication number Publication date
EP1299406B1 (en) 2005-10-26
WO2002002582A1 (en) 2002-01-10
US20030153512A1 (en) 2003-08-14
ATE307819T1 (en) 2005-11-15
DE10031955A1 (en) 2002-01-17
CA2414605A1 (en) 2002-12-30
DE50107844D1 (en) 2005-12-01
EP1299406A1 (en) 2003-04-09

Similar Documents

Publication Publication Date Title
AU2001275651A1 (en) Curcumin derivatives with improved water solubility compared to curcumin and medicaments containing the same
AU2119200A (en) Medicament
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
MXPA03005893A (en) Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs.
WO2001068092A3 (en) Glycogen phosphorylase inhibitor
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
WO2003080582A3 (en) Fredericamycin derivatives
WO1997002046A3 (en) Saccharide conjugates
WO2001087306A8 (en) Compositions and methods for the treatment of colorectal cancer
DE69834923D1 (en) Hochgradig lipophile camptothecin-derivate
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
WO2000066093A3 (en) Combined preparations comprising morpholine anthracyclines and anticancer agent
AU2002352531A1 (en) Use of at least one glycoinhibitor substance
IN188924B (en)
WO2002002189A3 (en) Cellulose sulfate and other sulfated polysaccharides to prevent and treat papilloma virus infection and other infections
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
AU2158601A (en) Antiviral agent for use in treatment of cancer
AU2002226030A1 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2005025501A3 (en) Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
AU2162202A (en) Antitumor therapy comprising distamycin derivatives
WO2005041881A8 (en) Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
EP1411956B8 (en) Use of oversulfated polysaccharides as inhibitors of hiv
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents